CryoCath Technologies
This article was originally published in The Gray Sheet
Executive Summary
Canadian initial public offering raises approximately $25.9 mil. (based on current exchange rates) to support clinical trials and commercialization of the Freezor focal ablation catheter system for tachyarrhythmia treatment, including atrial fibrillation. The funds also will go toward trials of the firm's CryoStent for post-angioplasty restenosis and CryoVasc system for cardiac ischemia. The offering included 5 mil. shares at about $5.17 each. The stock is listed on the Toronto exchange under the symbol "CYT." The IPO syndicate was led by Yorkton Securities and included CIBC World Markets, National Bank Financial and Loewen, Ondaatje, McCutcheon Limited